Lapatinib
From Proteopedia
(Difference between revisions)
(New page: ===Pharmacokinetics=== {| class="wikitable" border="1" width="40%" style="text-align:center" |- ! colspan="6" align="center"| Glitazone [[Pharmaceutical_Drugs#Pharmacokinetics_Translated...) |
|||
| Line 3: | Line 3: | ||
{| class="wikitable" border="1" width="40%" style="text-align:center" | {| class="wikitable" border="1" width="40%" style="text-align:center" | ||
|- | |- | ||
| - | ! colspan="6" align="center"| Glitazone [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] | + | ! colspan="6" align="center"| Glitazone [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] <ref>PMC:2679105</ref> |
|- | |- | ||
! Parameter | ! Parameter | ||
| Line 11: | Line 11: | ||
|- | |- | ||
! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr) | ! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr) | ||
| - | ! | + | ! 4 |
! Sunitinib (Sutent) | ! Sunitinib (Sutent) | ||
! Sorafenib (Nexavar) | ! Sorafenib (Nexavar) | ||
|- | |- | ||
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml) | ! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml) | ||
| - | ! | + | ! 115 |
! Sunitinib (Sutent) | ! Sunitinib (Sutent) | ||
! Sorafenib (Nexavar) | ! Sorafenib (Nexavar) | ||
| Line 31: | Line 31: | ||
|- | |- | ||
! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ||
| - | ! | + | ! 9.6 |
! Sunitinib (Sutent) | ! Sunitinib (Sutent) | ||
! Sorafenib (Nexavar) | ! Sorafenib (Nexavar) | ||
|- | |- | ||
! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ||
| - | ! | + | ! 1429 |
! Sunitinib (Sutent) | ! Sunitinib (Sutent) | ||
! Sorafenib (Nexavar) | ! Sorafenib (Nexavar) | ||
| Line 45: | Line 45: | ||
! Sorafenib (Nexavar) | ! Sorafenib (Nexavar) | ||
|- | |- | ||
| - | ! | + | ! Dosage (mg) |
| - | + | ! 100 | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | ! | + | |
! Sunitinib (Sutent) | ! Sunitinib (Sutent) | ||
! Sorafenib (Nexavar) | ! Sorafenib (Nexavar) | ||
Revision as of 07:51, 6 December 2010
Pharmacokinetics
| Glitazone Pharmacokinetics [1] | |||||
|---|---|---|---|---|---|
| Parameter | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Tmax (hr) | 4 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Cmax (ng/ml) | 115 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Bioavailability (%) | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Protein Binding (%) | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| T1/2 (hr) | 9.6 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| AUC (ng/ml/hr) | 1429 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| IC50 (nM) | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Dosage (mg) | 100 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Metabolism | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
